Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Acufol D3 is an oral nutraceutical combination product developed and marketed by Acure Pharma, an Indian pharmaceutical company. It is formulated as a tablet containing a combination of folate (likely in the form of L-methylfolate) and Vitamin D3 (cholecalciferol). The product is indicated for the management of folate and vitamin D deficiencies and as a general nutritional supplement. Folate is a critical cofactor in the folate metabolic pathway, essential for DNA synthesis, methylation, and red blood cell formation. Vitamin D3 acts as an agonist at the Vitamin D receptor (VDR), playing a vital role in calcium absorption, bone health, and immune system modulation. Acufol D3 is part of Acure Pharma's portfolio of marketed branded formulations and is intended to correct or prevent nutritional deficiencies in patients.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Acufol D3.